ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tinengotinib

Also written as “TT-00420”, “TT-00420 (tinengotinib)” and “tinengotinib 10 mg QD plus darolutamide”.

Its studies are mostly in Cholangiocarcinoma · Prostatic Neoplasms · Breast Neoplasms · Carcinoma, Hepatocellular · Triple Negative Breast Neoplasms, led by 2 companies.

Drug pageTinengotinib: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 29, 202311 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TransThera Sciences (Nanjing)its history only105 open or runningphase 3since Jun 29, 2023Aug 21, 2018Dec 2026phase 3 · NCT05948475
Akeso11 open or runningphase 2since Jun 26, 2025Jun 26, 2025May 10, 2027phase 2 · NCT07052253

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Akeso only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 25, 2022Named tinengotinibINNProposed as its International Nonproprietary Name in WHO's List 126 · before, TT-00420
  2. Jun 26, 2025First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT07052253 · 100 planned · China

Ahead

  1. May 10, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07052253

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Akeso leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07052253Carcinoma, Hepatocellular · China2RecruitingMay 10, 2027100

How it is read

Names in the registry

  • “TT-00420”, 4 entries
  • “TT-00420 (tinengotinib)”, 3 entries
  • “tinengotinib 10 mg QD plus darolutamide”, 1 entry
  • “tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide”, 1 entry
  • “tinengotinib 10 mg QD plus enzalutamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.